TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31629915
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four cycles followed by nivolumab 3 mg/kg every 2 weeks
Study: 25139589
Drug: Oxcarbazepine (1800-2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (1800-2400 mg)
Study: 20815183
Drug: Modafinil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (2 x 100 mg)
Study: 8564565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ATRA + chemotherapy
Study: 23447846
Drug: Fluid intake
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid intake of 300 ml/h
Study: 19920002
Drug: Insulin sensitization
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitization
Study: 19920002
Drug: Insulin provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin provision
Study: 15005471
Drug: School-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based oral health education programme
Study: 8767563
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam
Study: 16965682
Drug: Docetaxel (made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (made in Beijing) 75 mg/m² plus cisplatin 70 mg/m²
Study: 16965682
Drug: Docetaxel (made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (made in Jiangsu) 75 mg/m² plus cisplatin 70 mg/m²
Study: 15215483
Drug: Folate therapy
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate therapy
Study: 12767735
Drug: Standard haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard haemodialysis treatment
Study: 10867427
Drug: 40% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% chlorhexidine varnish (EC40) after dental treatment
Study: 10867427
Drug: Full dental
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dental treatment only
Study: 8637402
Drug: Melanotan-II (MT-II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanotan-II (MT-II) at doses of 0.01 mg/kg, escalated to 0.025 mg/kg and 0.03 mg/kg
Study: 3927332
Drug: Pizotifene (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifene (4 mg daily for 3 days orally)
Study: 3927332
Drug: Naloxone-HCI (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone-HCI (0.8 mg intravenously)
Study: 23300343
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment (control group)
Study: 2534552
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream
Study: 28794206
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) daily from ≤20 wk gestation to 6 mo postpartum
Study: 28794206
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient (MMN) capsule daily from ≤20 wk gestation to 6 mo postpartum
Study: 20495502
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin of < 9.0 g/dL)
Study: 15278580
Drug: 0.05 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg(‐1) vecuronium (low dose group)
Study: 6375469
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg t.i.d.)
Study: 17979579
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at a mean dose of 14.22 mg/day, n = 63
Study: 9537619
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion containing 154 microg phylloquinone
Study: 350904
Drug: 0.5% astringent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% astringent solution mouthwash
Study: 28116974
Drug: Original indications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original indications (19 drugs, 31 studies)
Study: 28116974
Drug: Supplemental indications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental indications (18 drugs, 33 studies)
Study: 9154884
Drug: Cefuroxime (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (two 1,500 mg doses 12 hours apart after intubation)
Study: 9154884
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cefuroxime, 17 patients received prophylactic antibiotics)
Study: 9154884
Drug: Control (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (patients receiving prior antibiotics)
Study: 9154884
Drug: Control (patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (patients not receiving prior antibiotics)
Study: 28643733
Drug: Gem/Cis (Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gem/Cis (Cisplatin 40 mg/m2 on day 1 and day 8 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Study: 22983820
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) added to Standard Care (SC)
Study: 20370452
Drug: Mupirocin applied
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin applied three times weekly (Group II)
Study: 20370452
Drug: Prior to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to mupirocin treatment
Study: 15071253
Drug: Atrial therapies
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial therapies OFF
Study: 26207129
Drug: Clzapine (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clzapine (generic formulation) 100 mg twice daily for 10 days
Study: 26207129
Drug: Clozaril (brand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozaril (brand name formulation) 100 mg twice daily for 10 days
Study: 24114865
Drug: High-dose β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β-blocker (≥50 mg daily equivalent dose of metoprolol succinate)
Study: 24114865
Drug: Low-dose β-blocker
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose β-blocker with high sST2
Study: 24114865
Drug: Low-dose β-blocker
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose β-blocker with low sST2
Study: 24114865
Drug: High-dose β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β-blocker with high sST2
Study: 18650733
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (group 1)
Study: 2405623
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium heparin
Study: 2405623
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium heparin
Study: 9184614
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 to 20 mg/day)
Study: 9754892
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro addition of LMWH (1.5 u aXa/ml)
Study: 26920668
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem
Study: 26157206
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (30 min/session, 3 sessions/week for 4 weeks)
Study: 16943451
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus 100 mg vitamin E
Study: 16943451
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus 200 mg vitamin E
Study: 16943451
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus 400 mg vitamin E
Study: 15364138
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiotherapy plus concomitant carboplatin (70 mg/m(2) intravenously for 5 days)
Study: 10660240
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine (0.125 mg/kg/h)
Study: 10660240
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine (0.25 mg/kg/h)
Study: 10660240
Drug: Saline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (6 to 11 mL/h)
Study: 8157048
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg i.v. dose of flumazenil
Study: 8157048
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral dose of flumazenil
Study: 3895918
Drug: Ceftazidime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (50 mg/kg intravenously every eight hours)
Study: 15254055
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (vincristine 2 mg/m(2), cyclophosphamide 1,200 mg/m(2), doxorubicin 75 mg/m(2) or dactinomycin 1.25 mg/m(2))
Study: 15254055
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (Regimen A alternating every 3 weeks with ifosfamide 1,800 mg/m(2)/d for 5 days and etoposide 100 mg/m(2)/d for 5 days)
Study: 11480629
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (no A/V eyeglasses)
Study: 7946694
Drug: Traditional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional surgical treatment of open carpal tunnel decompression
Study: 3060211
Drug: Methylphenidate (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (low-dose)
Study: 31101694
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric bupivacaine (1.15-1.70 mL) injected into the subarachnoid space without prophylactic vasopressors
Study: 31101694
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (1.8 mL) injected into the subarachnoid space along with prophylactic vasopressors
Study: 27491027
Drug: Sacral neuromodulation
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral neuromodulation (SNM) therapy with the InterStim® System
Study: 2185822
Drug: Mifepristone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 100 mg
Study: 9745414
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (including high dose i.v. methotrexate)
Study: 9745414
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose i.v. methotrexate
Study: 9745414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (children who did not receive high dose i.v. methotrexate)
Study: 7997610
Drug: Iopentol 350
Normalized name: iopentol 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol 350 mgI/ml
Study: 7997610
Drug: Iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 370 mgI/ml
Study: 3377206
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg lorazepam intravenously
Study: 3377206
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg secobarbital
Study: 30864279
Drug: Soybean oil-based
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil-based parenteral lipid emulsion (PLE), n = 35
Study: 7939369
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (3.4 g eicosapentaenoic and docosahexaenoic acid per day)
Study: 10322244
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg
Study: 21178598
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (240 mg lidocaine in 125 mL saline once a week for 4 weeks)
Study: 18315472
Drug: Terazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2 mg daily)
Study: 24455735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication)
Study: 12556735
Drug: Fenoldopam (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (a selective dopamine-1 receptor agonist)
Study: 25833022
Drug: Idazoxan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (40 mg)
Study: 25012003
Drug: Perindopril 5mg
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril 5mg daily for three months prior to surgery
Study: 25012003
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment daily for three months prior to surgery
Study: 11607795
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor treatment
Study: 15917842
Drug: Low-dose ghrelin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ghrelin infusion (1 pmol/kg/min)
Study: 15917842
Drug: High-dose ghrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ghrelin infusion (5 pmol/kg/min)
Study: 22133776
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg/day
Study: 7048770
Drug: unique dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unique dietary treatment
Study: 28952824
Drug: Simvastatin/beta-TCP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/beta-TCP combination
Study: 26787567
Drug: NAC 1200
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC 1200 mg orally before angiography and 1200 mg orally twice daily for three doses along with good hydration
Study: 26787567
Drug: NAC 600
Normalized name: Acetylcysteine 600 MG Oral Capsule [GNC NAC 600]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC 600 mg before angiography and 600 mg orally twice daily for three doses plus ascorbic acid (3000 mg one dose) before angiography and 2000 mg two doses after angiography and good hydration
Study: 26787567
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with 0.9% saline started just before contrast media injection and continued for 12 h at a rate 1.0 mL/kg/min after angiography or 0.5 mL/kg/h in cases with overt heart failure for 12 h
Study: 25194928
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy or occupational therapy (Control)
Study: 22244522
Drug: Tube shunt
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube shunt (350‐mm² Baerveldt glaucoma implant)
Study: 19584820
Drug: Glycosylated G-CSF
Normalized name: Glycosylated recombinant G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated G-CSF
Study: 9266953
Drug: Non-glycosylated G-CSF
Normalized name: Glycosylated recombinant G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-glycosylated G-CSF
Study: 17706004
Drug: Darifenacin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin (7.5 mg once daily for 2 weeks, then optional titration to 15 mg daily)
Study: 17706004
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with sham titration)
Study: 9929503
Drug: tizanidine HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tizanidine HCl, 4 mg t.i.d. for seven consecutive doses
Study: 9929503
Drug: both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: both regimens simultaneously for seven consecutive doses
Study: 11144
Drug: Cimetidine 50
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 50 mg
Study: 7135
Drug: Cimetidine 100
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 100 mg
Study: 29945431
Drug: Sufentanil 0
Normalized name: SUFentanil 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0 ng/mL
Study: 19258524
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine (PSE) HCl 15 or 30 mg
Study: 11941377
Drug: Paracetamol 600-650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 600-650 mg
Study: 28134543
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of evaluative statements and repeated evaluative pairings (ES + REP)
Study: 26248813
Drug: Dronabinol (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (5mg daily)
Study: 3117876
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg)
Study: 16918719
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg) and Erythromycin (1500 mg)
Study: 25391864
Drug: 80 kV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kV, Iodixanol (320 mgI/ml), SAFIRE
Study: 25391864
Drug: 80 kV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kV, Iopamidol (370 mgI/ml), SAFIRE
Study: 23461283
Drug: No IOP-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IOP-lowering medication
Study: 7989978
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial chemoembolization therapy using iodized oil (Lipiodol) before PET study
Study: 9519022
Drug: Benzocaine spray
Normalized name: benzocaine Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine spray
Study: 2742469
Drug: Air spray
Normalized name: hair spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air spray
Study: 2774884
Drug: Placebo (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (air spray)
Study: 1234015
Drug: Cardiorytmin Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiorytmin Retard (sustained-release preparation)
Study: 1234015
Drug: Pronestyl (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronestyl (conventional formulation)
Study: 30815685
Drug: HCMV glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCMV glycoprotein B/MF59 vaccine
Study: 26505753
Drug: Blood- plus
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood- plus liver-stage drugs (chloroquine [CQ], 3 d; artemether-lumefantrine [AL], 3 d; primaquine [PQ], 20 d, 10 mg/kg total dose)
Study: 26505753
Drug: Blood-stage drugs
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-stage drugs only (CQ, 3 d; AL, 3 d; placebo [PL], 20 d)
Study: 23102821
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus brief supportive psychotherapy
Study: 18973027
Drug: Votalin sustained
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Votalin sustained released tablets
Study: 31691133
Drug: Low-dose formulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose formulation
Study: 31691133
Drug: High-dose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose formulation
Study: 12594878
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg twice daily (intravenously or orally)
Study: 9039837
Drug: 55 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55 mmol/L glucose solution
Study: 9039837
Drug: Glucose-free solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-free solution
Study: 9039837
Drug: 110 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 mmol/L glucose solution
Study: 3228775
Drug: Combination drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drop
Study: 16573261
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole gel
Study: 31095868
Drug: 1-mL syringe
Normalized name: ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1-mL syringe with 30-G needle
Study: 31095868
Drug: 3-mL syringe
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mL syringe with 30-G needle
Study: 23638141
Drug: Titration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration at 0.5 μg/ml
Study: 23638141
Drug: Titration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration at 0.2 μg/ml
Study: 23638141
Drug: Titration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration at 0.1 μg/ml
Study: 23638141
Drug: Induction Ce
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Ce of propofol at 0.5 μg/ml
Study: 23638141
Drug: Induction Ce
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Ce of propofol at 0.2 μg/ml
Study: 23638141
Drug: Induction Ce
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Ce of propofol at 0.1 μg/ml
Study: 26864356
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (22 g), essential amino acids (10.9 g, including 4 g leucine), and vitamin D [2.5 μg (100 IU)] with physical activity
Study: 20814119
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily for 10 days
Study: 17986904
Drug: 6.4% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate-electrolyte solution (CHO-E)